Navigation Links
Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
Date:12/21/2007

EMERYVILLE, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI (R)) (Nasdaq: NTII) today announced the retirement of Dr. Ronald E. Cape as Director, effective December 31, 2007.

Paul Freiman, president and chief executive officer stated, "We have accepted Dr. Cape's resignation upon the occasion of his 75th birthday. Dr. Cape is a legend in the biotechnology industry and his service on our board has been outstanding. Prior to joining the board, Dr. Cape served as an advisor to the company and we are pleased that he has agreed to continue to be available to advise us."

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The Company is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
2. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
3. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
4. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
5. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
10. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
11. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... , May 6, 2015  Oxis Biotech, Inc. (OXIS), ... OXIS, OXI.PA, announced today that Cassian Yee , ... Cancer Medicine at the University of Texas MD Anderson ... is also Professor, Department of Immunology, Division of Cancer ... Cancer Immunology Research at the University of Texas MD ...
(Date:5/6/2015)... Portland, OR (PRWEB) May 06, 2015 ... executive search and growth strategy for the specialty pharmacy ... Sponser of the 2015 Armada Specialty Pharmacy Summit. The ... Wynn Hotel in Las Vegas and is the largest ... people will be in attendance, from pharmacy providers, pharma/biotech ...
(Date:5/5/2015)... May 5, 2015  23andMe, Inc., the leading personal ... Lupus Research Study in collaboration with Pfizer Inc. ... lupus erythematosus, more commonly known as lupus, into the ... The effort is also in collaboration with the Lupus ... in May. Approximately 1.5 million people in ...
(Date:5/5/2015)... , May 5, 2015  Tikcro Technologies ... was approved to continue trading on OTCQB  Marketplace, ... OTCQB Marketplace allows for a continuous public ... Investors can have real-time quotes and market information ... The OTCQB Marketplace includes U.S. and international ...
Breaking Biology Technology:Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 2Oxis Biotech Appoints Cassian Yee, M.D. To Its Scientific Advisory Board 3The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 223andMe Launches the Lupus Research Study in Collaboration with Pfizer Inc. 3Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2
... 23 Pharmaceutical and biotech partners tasked with cutting costs and improving ... What are the implications of the current economic ... can I harness the knowledge of all employees to improve processes cross-functionally? ... methodologies do I use to show the revenue of quality instead of ...
... WYE ) announced today that it will ... Stock, par value $2.50 per share (the "Convertible Preferred ... As of April 22, 2009, there were 8,896 ... each share of Convertible Preferred Stock is $60.08, which ...
... Provide Proprietary Protein and Small Molecule Products for ... Stem (iPS) CellsLA JOLLA, Calif. and BOSTON, April ... and Stemgent, Inc. ... one-of-a-kind program to provide pharmaceutical and biotechnology companies ...
Cached Biology Technology:Cost-Cutting Plus Value-Add Defines Quality's Role in a Recession 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 2Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 3Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 4Wyeth Announces Full Redemption of $2 Convertible Preferred Stock 5Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 2Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 3Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology 4
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/26/2015)... March 26, 2015 The Granite ... recreation and athletic club, today announced it has implemented ... freedom of movement for members and staff, while restricting ... comprehensive process, we selected FST,s IMID Access system because ... for our members and staff, in addition to unparalleled ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... in the open-access journal PLoS Biology, streamlines the computation ... genome that influence a particular physical trait, or phenotype. ... Joshua M. Akey, and Leonid Kruglyak, researchers have a ... the genomic elements that produce specific traits. , In ...
... gene therapy can promote the growth of new "insulation" around ... new study shows. The treatment, which mimics the activity of ... and electrical conduction from the brain to the leg muscles. ... spinal cord injury in humans. The study was funded in ...
... results of a study conducted at Johns Hopkins show that ... attacks, or myocardial infarction, in pigs. In just two months, ... into the animal's damaged heart restored heart function and repaired ... The Hopkins findings, first presented last fall at the 2004 ...
Cached Biology News:Improved statistical tools reveal many linked loci 2Combination therapy leads to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats 3Stem cell therapy successfully treats heart attack in animals 2
Mol wt: average mol wt12,360.96 Da by calculation...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... Adaptor encodes a T7 promoter, lac ... translation initation codon and an N-terminal GST•Tag ... reported to enhance the production and in ... partners. The GST•Tag is a multi-purpose tag ...
A cost-effective serum for general cell growth requirements. All serum is collected from calves aged 10 days old or less....
Biology Products: